Amaurosis fugax mit erhöhten Akutphasenproteinen

Case report of a 66-year-old woman with episodes of amaurosis fugax and hemicranic headache with otherwise normal ophthalmologic and neurological examinations and normal imaging. While ESR was in the normal range for patient's age, acute phase proteins (C-reactive protein and fibrinogen) were elevated. Giant cell arteritis was proved by temporal artery biopsy. Giant cell arteritis should be considered as an important differential diagnosis of amaurosis fugax even in patients with normal ESR. Acute phase protein testing can give relevant diagnostic information.

Energie

Le Conseil fédéral a mis en consultation la Stratégie énergétique 2050. – L’initiative populaire des Vert’libéraux destinée à introduire une réforme fiscale écologique a abouti. – Swissgrid a repris le réseau suisse de transport de l'électricité. – Les Verts ont déposé une initiative populaire demandant la sortie de l’énergie nucléaire. – Des experts ont émis des doutes quant à l’indépendance des instances de sécurité nucléaire. – Le Tribunal fédéral administratif a fixé un délai à l’exploitation de la centrale nucléaire de Mühleberg.

PCSK9 inhibitors: emerging treatment to lower cholesterol?

The achievement rate of recommended low-density lipoprotein cholesterol (LDL-C) targets of < 1.8 mmol/l for secondary prevention in very high risk patients is difficult. Observational studies reported that loss of function mutation of the PCS9 was associated with LDL-C decrease level and reduction of cardiovascular events. Monoclonal antibodies to PCSK9 (REGN727 and AMG 145, PSCK9 inhibitors) have been tested in clinical studies of phase I and II and showed LDL-C level reduction of 60-70% compared to placebo. This approach appears safe and well-tolerated. The PCSK9 inhibitors are now tested in large phase III clinical studies to assess the long-term safety and efficacy of this new promising approach.